However , key secondary endpoints were met : the mean 4 h C-peptide AUC was significantly higher ( mean increase of 0.015 nmol/L [ 95 % CI -0.076 to 0.106 ] vs decrease of -0.156 nmol/L [ -0.305 to -0.006 ] ; p = 0.019 ) , and daily insulin use ( 0.48 units per kg per day for placebo vs 0.36 units per kg per day for alefacept ; p = 0.02 ) and the rate of hypoglycaemic events ( mean of 10.9 events per person per year for alefacept vs 17.3 events for placebo ; p < 0.0001 ) was significantly lower at 12 months in the alefacept group than in the placebo group .